Cancer Research Infection and Cancer: Biology, Therapeutics, and Prevention  Translational Medicine Conference in Israel
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

[Cancer Research 47, 4335-4337, August 15, 1987]
© 1987 American Association for Cancer Research

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Cohen, J. D.
Right arrow Articles by Robins, H. I.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Cohen, J. D.
Right arrow Articles by Robins, H. I.

Hyperthermic Enhancement of cis-Diammine-1,1-cyclobutane Dicarboxylate Platinum(II) Cytotoxicity in Human Leukemia Cells in Vitro1

Justin D. Cohen2 and H. Ian Robins3

Department of Human Oncology, University of Wisconsin Clinical Cancer Center, University of Wisconsin Clinical Science Center, Madison, Wisconsin 53792

Hyperthermic enhancement of cis-diammine-1,1-cyclobutane dicarboxylate platinum(II) (carboplatin) cytotoxicity was studied in vitro in JM, a human acute lymphoblastic leukemia cell line. Corrected for direct heat toxicity, hyperthermia enhanced carboplatin killing at the clinically relevant temperatures of 40.5° and 41.8°C. The thermal enhancement ratios at these temperatures were 1.89 and 3.32, respectively. Cell killing increased exponentially with increasing duration of combined treatment (41.8°C, carboplatin 30 µg/ml) for at least 3.5 h. Hyperthermic enhancement was maximal when heat was given during or immediately before carboplatin; enhancement was diminished when heat preceded carboplatin by more than an hour and was not apparent when heat followed drug treatment.

As carboplatin is associated with different clinical toxicity than is cis-diamminedichloroplatinum(II), carboplatin may represent an ideal drug in its class of anticancer agents to use in clinical whole body hyperthermia trials.

1 Supported by Midwest Athletes Against Childhood Cancer.

2 An American Cancer Society Clinical Oncology Fellow.

3 An American Cancer Society Fellow. Supported in part by Grant RO1-CA-35361. To whom requests for reprints should be addressed, at Department of Human Oncology, University of Wisconsin, Clinical Cancer Center, 600 Highland Avenue, Madison, WI 53792.

Received 2/ 6/87. Revised 5/21/87. Accepted 5/27/87.




This article has been cited by other articles:


Home page
Ann OncolHome page
H. Tsuda, M. Tanaka, T. Manabe, H. Ikeda, S. Negoro, O. Ishiko, and K. Yamamoto
Phase I study of combined radiation, hyperthermia and intra-arterial carboplatin for local recurrence of cervical cancer
Ann. Onc., February 1, 2003; 14(2): 298 - 303.
[Abstract] [Full Text] [PDF]


Home page
RadiologyHome page
P. Chang, M. D. Sapozink, S. M. Grunberg, G. Jozsef, D. M. Rice, S. C. Formenti, and O. E. Streeter Jr
Unresectable Primary and Recurrent Head and Neck Tumors: Effect of Hyperthermia and Carboplatin-Preliminary Experience
Radiology, March 1, 2000; 214(3): 688 - 692.
[Abstract] [Full Text]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 1987 by the American Association for Cancer Research.